title: Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.
abstract: PRL exists in different forms in human serum. The predominant form is little PRL (molecular mass 23 kDa) with smaller amounts of big PRL (molecular mass 50--60 kDa) and at times big big or macroprolactin (molecular mass 150--170 kDa). The frequency and clinical consequences of macroprolactinemia have not been clearly established, mainly because of difficulty in identifying these patients biochemically. This previously required the use of gel filtration chromatography, which could not be used routinely. Recently, a screening test using polyethylene glycol (PEG) has been used to identify macroprolactin in serum. Consequently, this study was designed to examine the use of PEG precipitation in the identification of patients with a predominance of macroprolactin and to establish the clinical characteristics of such a cohort. Over 12 months, 18,258 requests for serum PRL were received and of these 1225 patients had a serum PRL more than 700 mU/L. A total of 322 of these patients (26%) had a percentage recovery after PEG precipitation of less than 40%, thus indicating the presence of a predominance of macroprolactin. Fifty-five of these patients were referred for detailed clinical assessment. Symptoms typical of hyperprolactinemia were not common in this cohort. None had sustained amenorrhea and eight have had oligomenorrhea at age less than 40 yr. One had galactorrhea. All had pituitary imaging, and four had a microadenoma with none having a macroadenoma. PEG precipitation allows easy identification of macroprolactin in routine clinical practice. As the clinical consequences of this entity at this stage seem relatively benign, referral and intensive investigation of these patients may not be necessary. However, follow-up of a large cohort is required to ensure that the long-term outlook is likewise benign. This would have important implications for both patients and healthcare systems.
authors.affiliation: Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast, United Kingdom BT12 6BA.
authors.forename: H
authors.initials: H
authors.lastname: Leslie
authors.forename: C H
authors.initials: CH
authors.lastname: Courtney
authors.forename: P M
authors.initials: PM
authors.lastname: Bell
authors.forename: D R
authors.initials: DR
authors.lastname: Hadden
authors.forename: D R
authors.initials: DR
authors.lastname: McCance
authors.forename: P K
authors.initials: PK
authors.lastname: Ellis
authors.forename: B
authors.initials: B
authors.lastname: Sheridan
authors.forename: A B
authors.initials: AB
authors.lastname: Atkinson
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D000077465:Cabergoline; D015331:Cohort Studies; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D005298:Fertility; D006261:Headache / Q000097:blood; D006801:Humans; D008279:Magnetic Resonance Imaging; D008499:Medical Records; D008598:Menstruation; D008599:Menstruation Disturbances / Q000097:blood / Q000188:drug therapy; D008875:Middle Aged; D010902:Pituitary Gland / Q000000981:diagnostic imaging / Q000473:pathology; D011092:Polyethylene Glycols; D011388:Prolactin / Q000097:blood*; D014057:Tomography, X-Ray Computed
chemical_list: D004873:Ergolines; C060678:prolactin, polymeric; D001971:Bromocriptine; D011092:Polyethylene Glycols; D011388:Prolactin; D000077465:Cabergoline